Human monoclonal antibodies to sialyl-Lewisa (CA19.9) with potent CDC, ADCC, and antitumor activity

Clinical Cancer Research

Volumn 17, Issue 5, 2011, Pages 1024-1032

  Sawada, Ritsuko ^a   Sun, Shu Man ^a   Wu, Xiaohong ^b   Hong, Feng ^b   Ragupathi, Govind ^b   Livingston, Philip O ^b   Scholz, Wolfgang W ^a  

^a MabVax Therapeutics Inc   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCAN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CA19.9; N ACETYLGLUCOSAMINE; SIALYL LEWIS X ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL TIME; TUMOR; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CA-19-9 ANTIGEN; CELL LINE, TUMOR; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, SCID; NATURAL KILLER T-CELLS; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952254471     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2640     Document Type: Article

References (23)

1. Feizi T. Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens. Nature 1985;314:53-7. (Pubitemid 15142022)
2. Lloyd KO. Molecular characteristic of tumor antigens. Immunol Allergy Clin N America 1990;10:765-79.
3. Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M. Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 1995;75: 2051-6.
4. Kannagi R. Carbohydrate antigen sialyl Lewis a-its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 2007;30:189-209. (Pubitemid 47235445)
5. Kawamura YI, Kawashima R, Fukunaga R, Hirai K, Toyama-Sorimachi N, Tokuhara M, et al. Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis. Cancer Res 2005;65:6220-7. (Pubitemid 40994407)
6. Ben-David T, Sagi-Assif O, Meshel T, Lifshitz V, Yron I, Witz IP. The involvement of the sLe-a selectin ligand in the extravasation of human colorectal carcinoma cells. Immunol Lett 2008;116:218-24.
7. Sato M, Narita T, Kimura N, Zenita K, Hashimoto T, Manabe T, et al. The association of sialyl Lewis(a) antigen with the metastatic potential of human colon cancer cells. Anticancer Res 1997;17:3505-11. (Pubitemid 27522317)
8. Matsui T, Kojima H, Suzuki H, Hamajima H, Nakazato H, Ito K, et al. Sialyl Lewisa expression as a predictor of the prognosis of colon carcinoma patients in a prospective randomized clinical trial. Jpn J Clin Oncol 2004;34:588-93. (Pubitemid 40662713)
9. Kishimoto T, Ishikura H, Kimura C, Takahashi T, Kato H, Yoshiki T. Phenotypes correlating to metastatic properties of pancreas adenocarcinoma in vivo: the importance of surface sialyl Lewis(a) antigen. Int J Cancer 1996;69:290-4. (Pubitemid 26298293)
10. Steplewska-Mazur K, Gabriel A, Zajecki W, Wylezol M, Gluck M. Breast cancer progression and expression of blood group-related tumor-associated antigens. Hybridoma 2000;19:129-33. (Pubitemid 30387231)
11. Ragupathi G, Damani P, Srivastava G, Srivastava O, Sucheck SJ, Ichikawa Y, et al. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine. Cancer Immunol Immunother 2009;58:1397-405.
12. Pettengill OS, Sorenson GD, Wurster-Hill DH, Curphey TJ, Noll WW, Cate CC, et al. Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer 1980;45:906-18. (Pubitemid 10129840)
13. Sawada-Hirai R, Jiang I, Wang F, Sun SM, Nedellec R, Ruther P, et al. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J Immune Based Ther Vaccines 2004;2:5.
14. Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000;6:1693-701. (Pubitemid 30305061)
15. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A 2001;98:3270-5. (Pubitemid 32220835)
16. Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res 2003;9:5214-20. (Pubitemid 37413571)
17. Ragupathi G, Meyers M, Adluri S, Howard L, Yu RK, Ritter G, et al. Phase I trial with GD3-lactone-KLH conjugate and immunological adjuvant QS-21 vaccine with malignant melanoma. Int J Cancer 2000;85:659-66. (Pubitemid 30080479)
18. Dickler MN, Ragupathi G, Liu NX, Musselli C, Martino DJ, Miller VA, et al. Immunogenicity of the fucosyl-GM1-keyhole limpet hemocyanin (KLH) conjugate vaccine in patients with small cell lung cancer. Cancer Res 1999;5:2773-9,. (Pubitemid 29493951)
19. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res 2008;36:W503-8.
20. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE. Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 1990;50:2183-90. (Pubitemid 20115097)
21. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993;261:212-5. (Pubitemid 23265398)
22. Kohls MD, Lappi DA. Mab-ZAP: a tool for evaluating antibody efficacy for use in an immunotoxin. Biotechniques 2000;28:162-5. (Pubitemid 30036834)
23. Ugorski M, Laskowska A. Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 2002;49:303-11. (Pubitemid 135686776)